Edwin L. Madison

Mosaic Biosciences, Inc. provides commercial research and development services. It conducts research on synthetic materials that support native tissue regeneration. The firm's solutions are designed for application in wound healing, bone regeneration, cartilage repair, stem cell therapy, and dermal fillers. The company was founded by Martin Stanton, Chris Bowman, Kristi S. Anseth and Peter Mariner in 2009 and is headquartered in Boulder, CO.

Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California.

QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA.

NexEos Bio is a medical diagnostics company that aims to improve the detection, diagnosis, treatment, and management of patients with chronic, eosinophil-related inflammatory diseases. The company is based in Wayne, PA. The company's lead program is a non-invasive imaging agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis (EoE). This program has the potential to improve patients' quality of life, more rapidly diagnose their disease, and may help delay disease progression. The company was founded by Gerald Gleich, and the CEO is Theresa Mansi.

NexEos Diagnostics, Inc. operates as a medical diagnostics company focuses on disorders related to white blood cells. The company is headquartered in Wayne, PA.

SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million.

ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA.

Georgia Venture Partners LLC(Georgia Venture Partners) is an Independent Venture Capital firm founded in 2004 by John P. Richard and Thomas H. Callaway. The firm is headquartered in Atlanta.

Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ.

TeneoBio, Inc. operates as a biotechnology company that develops biologics, human heavy chain antibodies, as therapeutics against cancer, autoimmunity, and infectious diseases. Its products provides treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. The company was founded by Roland Buelow, on August 9, 2009 and is headquartered in Menlo Park, CA.

Abeome Corp. operates as a biotechnology company. It develops therapeutic and diagnostic monoclonal antibodies (mAbs). The firm’s DiSH (Direct Selection of Hybridomas) technology offers a process for selecting and cloning desired hybridomas that produce antibodies with optimal binding characteristics. The company was founded by Richard B. Meagher in 2000 and is headquartered in Athens, GA.

Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA.

Altiris Therapeutics, Inc. develops and commercializes small-molecule drug therapies. The company was founded by Dennis Liotta, Hyunsuk Shim and James P. Snyder in 2005 and is headquartered in Atlanta, GA.

Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK.

Aruna Bio, Inc. manufactures and provides neural stem cells. Its products include neuronet pure human neurons screening kit, neuronet pure human neurons discovery kit, co-culture kit hastropro-neuronet, hastropro human astrocytes kit and motor neurons GFP+htscreening kit. The company was founded by James Stice and Steven L. Stice in 2003 and is headquartered in Athens, GA.

Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom.

Essex Woodlands Health ventures Fund LP invests in startups and buyout stage industries and also focus in the areas like Pharmaceuticals, Biotechnology, Medical Devices, Health Services, Managed Care and Health Information.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001.

Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX.

Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA.

Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California.

Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA.

Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany